Foley & Lardner LLP represented AXA IM Alts, a global leader in alternative investments, as the lead investor in the $26 million Series A financing round for Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and leader in real-world applications for AI Eye Screening and AI Predictive Biomarkers.
Eyenuk will use the capital to expand its AI product platform with additional disease indications and advanced care coordination and accelerate the platform’s global commercialization and adoption.
Eyenuk is leading the way in harnessing the power of AI to eliminate preventable blindness globally through its versatile digital health platform that enables automated AI diagnosis and coordination of care. Eyenuk’s flagship EyeArt AI system has been more broadly adopted worldwide than any other autonomous AI technology for ophthalmology. It is the first and only technology to be cleared by the FDA for autonomous detection of both referable and vision-threatening diabetic retinopathy without any eye care specialist involvement.
The Foley team representing AXA IM Alts was led by Partner Julie-Anne Lutfi and included Associates Justin Lauria-Banta and Graham MacEwan.
About Foley & Lardner LLP
Foley & Lardner LLP is a preeminent law firm that stands at the nexus of the energy, health care and life sciences, innovative technology, and manufacturing sectors. We look beyond the law to focus on the constantly evolving demands facing our clients and act as trusted business advisors to deliver creative, practical, and effective solutions. Our 1,100 lawyers across 25 offices worldwide partner on the full range of engagements from corporate counsel to IP work and litigation support, providing our clients with a one-team solution to all their needs. For nearly two centuries, Foley has maintained its commitment to the highest level of innovative legal services and to the stewardship of our people, firm, clients, and the communities we serve.
